Chang-Han Lee

Assistant Professor

Seoul National University

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Chang-Han Lee is an Assistant Professor at Seoul National University, South Korea. His research areas focus on immunology and infectious diseases, highlighted by recent articles on SARS-CoV-2 antibody responses, chimeric antigen receptor-T cell function, and the development of novel biosensors. He also explores the clinical outcomes of COVID-19 patients undergoing specific therapies and the dynamics of immune responses following vaccination.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Todd Triplett

Assistant Professor (tenure track)

Texas Tech University Health Sciences Center

UNITED STATES

View details

Hong Bin Kim

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Jiwon Lee

Assistant Professor

Dartmouth College

UNITED STATES

View details

Keehoon Jung

Seoul National University College of Medicine

SOUTH KOREA

View details

Minji Kim

Seoul National University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Chang-Han Lee

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Novel FRET‐based Immunological Synapse Biosensor for the Prediction of Chimeric Antigen Receptor‐T Cell Function

Anti-SARS-CoV-2 Nucleocapsid Antibody Positivity Three Years after COVID-19

Construction and validation of a synthetic phage-displayed nanobody library

Clinical outcomes and immunological features of COVID-19 patients receiving B-cell depletion therapy during the Omicron era

Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19

Tracking antigen‐specific TCR clonotypes in SARS‐CoV‐2 infection reveals distinct severity trajectories

Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once‐boosted BA.1/2 convalescents and twice‐boosted COVID‐19‐naïve individuals

Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model

Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection

Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer

Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy

Computer‐based engineering of thermostabilized antibody fragments

Tumor-associated myeloid cells provide critical support for T-ALL

Collaborators (5)

Todd Triplett

Hong Bin Kim

Jiwon Lee

Keehoon Jung

Minji Kim

Make your next move.